Browse the evidence

Liraglutide (3 mg once daily) produces a mean weight loss of 8% over 56 weeks in patients without diabetes.

If you are prescribed Liraglutide (Saxenda), expect to take a 3 mg injection once daily. This can lead to an 8% reduction in body weight over 56 weeks. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Subcutaneous semaglutide (up to 1.0 mg once-weekly) produces significantly greater reductions in BMI and waist circumference compared to liraglutide (up to 3.0 mg once-daily) in obese patients with type 2 diabetes over a 12-month period, while both agents significantly lower HbA1c.

For obese patients with type 2 diabetes, switching from or choosing semaglutide over liraglutide is likely to result in greater weight loss and waist circumference reduction. While both drugs effectively lower blood sugar, semaglutide offers superior body composition benefits. Patients should be aware that gastrointestinal side effects are common, especially with semaglutide, but these often subside as the dose is titrated up.

Obesity pharmacotherapy (GLP-1/GIP agonists) reduces body weight with minimal loss of lean mass and improves cardiovascular outcomes, potentially mitigating the adverse effects of intermittent fasting.

If you are considering obesity pharmacotherapy (like GLP-1 agonists), know that it can lead to significant weight loss (up to 21% in some trials) with minimal loss of muscle mass, which is a key advantage over intermittent fasting. It also reduces cardiovascular risk. However, long-term safety is still being studied, and combining it with lifestyle changes (diet and exercise) is recommended for the best outcomes.

Performing past-failure partial repetitions in the lengthened position after reaching momentary failure during standing calf raises increases medial gastrocnemius hypertrophy compared to terminating sets at momentary failure in peak plantarflexion.

If you do calf raises, don't stop when you can no longer lift your heels all the way up. Once you fail a full repetition, immediately drop the heel as low as possible and do partial up-and-down movements until you can't lift your heels to that lowest point anymore. This adds significant volume and tension to the muscle, leading to more growth than stopping at the point of failure. Expect it to be uncomfortable, but for many, the extra growth is worth it.

Resistance training improves handgrip strength in older adults with sarcopenia, with an optimal dose of 3 sessions/week at 49% 1RM, 19 weeks duration, 15 exercises, 16 reps, 6 sets, totaling 1,400 reps/week.

If you are an older adult with sarcopenia, aim for 3 resistance training sessions per week. Use a weight that feels like 49% of your maximum lift (moderate effort). Perform 15 different exercises, doing 6 sets of 16 repetitions for each. Keep your total weekly repetitions around 1,400. Stick to this plan for 19 weeks to see the best improvement in your handgrip strength.

Fasting interventions significantly reduce liver health biomarkers (ALT and liver stiffness) in individuals with MASLD compared to control diets.

For those with MASLD, structured fasting approaches (like Alternate Day Fasting, 5:2 diets, or Time-Restricted Eating) have been shown in meta-analyses to significantly lower liver enzymes (ALT) and reduce liver stiffness compared to control diets. These benefits are linked to improvements in insulin resistance and triglyceride levels. Most effective studies lasted 3 months, so long-term sustainability needs more research, but the short-term liver health gains are robust.

The Mediterranean Diet (MedDiet) significantly improves liver health biomarkers (ALT, liver stiffness, and MRI-PDFF) in individuals with MASLD.

Adhering to a Mediterranean Diet significantly improves liver health in people with MASLD, lowering liver enzymes, reducing liver stiffness, and decreasing liver fat content. Studies lasted from 3 to 24 months, showing consistent benefits. This dietary pattern is a strong, evidence-based first-line approach for managing liver health.

Consuming ≥2 servings/week of sugar-sweetened beverages (SSBs) or artificially sweetened beverages (ASBs) is associated with a significantly higher risk of type 2 diabetes, even among adults who meet physical activity guidelines.

If you drink sugary or artificially sweetened beverages frequently (≥2 servings/week), your risk of type 2 diabetes increases, even if you exercise regularly. While exercise helps mitigate this risk, it does not cancel it out. To lower your diabetes risk, you should reduce your intake of these beverages in addition to staying active.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) achieve weight loss magnitudes (15-20%) comparable to bariatric surgery, significantly outperforming older pharmacotherapies and single-agonist GLP-1s.

If you have obesity, newer dual-agonist medications (like tirzepatide) are currently the most effective non-surgical treatment available, offering weight loss results similar to bariatric surgery. They work by targeting multiple hormonal pathways to reduce appetite and improve metabolism. Consult a doctor to see if you qualify based on your BMI and comorbidities.

Early response to treatment (≥5% weight loss in 3 months) is a strong predictor of long-term success; non-responders should switch therapies.

Monitor your weight closely in the first 3 months of starting a new obesity medication. If you haven't lost at least 5% of your body weight, talk to your doctor about switching to a different therapy. Early success is the best predictor of long-term success.

Endoscopic Sleeve Gastroplasty (ESG) using full-thickness suturing produces durable weight loss (mean 64-67% Excess Weight Loss at 12 months) and significant improvement/remission of metabolic comorbidities (T2DM, hypertension, NAFLD) in patients with BMI 30-50 kg/m2, outperforming lifestyle modifications and intragastric balloons.

ESG is a minimally invasive endoscopic procedure that reduces stomach volume and delays emptying to promote satiety. It is suitable for adults with BMI 30-50 who want a durable alternative to lifestyle changes or balloons, with high success rates for weight loss and metabolic improvement. It requires general anesthesia and has a low risk of serious complications.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, produces significant, dose-dependent reductions in body weight, BMI, and metabolic markers in obese adults with or without type 2 diabetes.

Retatrutide is a weekly injection that significantly reduces body weight (average ~14%) and improves metabolic health in obese adults, including those with type 2 diabetes. It works by targeting three hormone receptors (GLP-1, GIP, glucagon) to reduce appetite and improve insulin sensitivity. Higher doses (8-12 mg) generally produce greater weight loss. Common side effects include nausea and vomiting, which are often manageable. It is a prescription medication requiring medical supervision.

Combining bimagrumab (30 mg/kg IV every 12 weeks) with semaglutide (2.4 mg SC weekly) produces synergistic weight loss and body recomposition, achieving significantly greater fat mass reduction and lean mass preservation than either drug alone.

If you have obesity, combining a muscle-preserving antibody (bimagrumab) with a standard GLP-1 drug (semaglutide) yields significantly more fat loss and better muscle retention than using semaglutide alone. This suggests that targeting muscle preservation directly can enhance the efficacy of standard weight loss therapies.

Sustained, non-surgical, non-pharmacological weight loss from overweight (BMI ≥25) to healthy weight (BMI <25) during midlife (ages 40-50) is associated with a significantly decreased risk of incident chronic diseases (excluding type 2 diabetes) and all-cause mortality compared to persistent overweight.

If you are in midlife (40s-50s) and currently overweight, achieving and maintaining a healthy BMI (under 25) through lifestyle changes (diet and exercise) significantly lowers your risk of developing chronic diseases and dying prematurely compared to staying overweight. This benefit is independent of diabetes risk and does not require surgery or medication. The key is sustainability; the health benefits accrue over decades.

Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, produces significant, dose-dependent weight loss in adults with obesity or overweight (≥1 comorbidity) over 13 weeks, with the 15 mg dose achieving a mean 14.7% reduction.

Take VK2735 once weekly as prescribed. Start with the lowest dose (2.5 mg) and follow the titration schedule to minimize side effects. Combine with a 500 kcal daily caloric deficit and 150 minutes of exercise per week for best results. Expect significant weight loss (up to 14.7% at 15 mg) within 13 weeks, with side effects like nausea typically subsiding after the titration phase.

Newer obesity management medications (OMMs), specifically semaglutide (2.4 mg) and tirzepatide (10-15 mg), demonstrate high efficacy comparable to metabolic bariatric surgery (MBS) in the short term (26-52 weeks), with tirzepatide achieving >15% TBWL.

For those seeking non-surgical weight loss, newer medications like semaglutide (2.4 mg) and tirzepatide (10-15 mg) are the most effective options available, with tirzepatide showing short-term weight loss (15.2%) comparable to surgical procedures. These require weekly administration and are generally more effective than older medications like orlistat. They are best used in conjunction with lifestyle interventions.

Combining exercise with pharmacotherapy (specifically GLP-1 agonists or orlistat) significantly enhances weight loss, BMI reduction, and body fat percentage compared to exercise alone in overweight/obese adults.

If you are overweight or obese, adding a prescribed weight-loss medication (like GLP-1 agonists or orlistat) to your regular exercise routine will likely result in greater weight and fat loss than exercising alone. While exercise is foundational, medication can help overcome compensatory mechanisms like increased appetite, leading to more significant improvements in body composition.

A modified-release combination of orlistat (120 mg) and acarbose (40 mg) produces significantly greater weight loss (mean -7.73%) compared to modified-release orlistat alone (-5.78%) or conventional orlistat (-5.13%) over 26 weeks.

Take the specific combination pill (EMP16) containing 120mg modified-release orlistat and 40mg modified-release acarbose daily with meals for 6 months. Follow a diet limiting fat to 30% of calories and focusing on low-glycemic foods. Expect roughly 7.7% body weight loss, which is significantly better than taking orlistat alone.

Tirzepatide demonstrates greater comparative weight loss and metabolic benefits than semaglutide in real-world observational studies, particularly in patients without pre-existing diabetes.

If you are using Semaglutide and not achieving your weight loss goals, switching to Tirzepatide may result in greater weight loss and better metabolic outcomes, especially if you do not have Type 2 Diabetes. Real-world data suggests Tirzepatide is more potent than Semaglutide in routine practice.

Skeletal Muscle Mass (SMM) and Appendicular Lean Soft Tissue (ALST) are critical protective factors against frailty, diabetes, and mortality, and their loss (sarcopenia) is an independent risk factor for adverse health outcomes.

Prioritize resistance training to build and maintain muscle mass, especially as you age. Muscle is not just for aesthetics; it is your primary organ for glucose disposal and metabolic health. If you are losing weight, ensure you are doing resistance training and consuming adequate protein to prevent muscle loss, which can lead to frailty and weight regain.

Animal protein improves muscle mass compared to non-soy plant proteins (rice, chia, oat, potato) and plant-based diets, while soy protein is equivalent to milk protein for muscle mass.

If you are using plant protein, soy is just as good as animal protein for building muscle. Other plant proteins (rice, pea, oat, potato) may be less effective, so consider combining them or supplementing with soy or animal protein if muscle mass is a priority.

Combining GLP-1 receptor agonists (GLP-1RAs) with lifestyle modifications results in significantly greater weight loss and improved cardiometabolic biomarkers compared to lifestyle modifications alone in adults with overweight or obesity.

If you have overweight or obesity, combining a GLP-1 receptor agonist (like semaglutide or liraglutide) with lifestyle changes (calorie restriction and regular exercise) is significantly more effective for weight loss and improving heart health markers than lifestyle changes alone. To minimize muscle loss, ensure your lifestyle intervention includes resistance training. Consult a doctor to determine if GLP-1RAs are appropriate for you.

Early and lifelong treatment of obesity is critical to prevent weight recurrence, preserve lean body mass, and reduce cardiometabolic risk.

Treat obesity as a chronic condition requiring lifelong management, not a short-term diet. Focus on early intervention to prevent complications and preserve muscle mass. Use comprehensive strategies including nutrition, physical activity, behavioral counseling, and medical interventions as needed. Regular follow-ups are essential to maintain health and prevent weight recurrence.

Treatment with tirzepatide (10 or 15 mg) produces a significantly greater reduction in predicted 10-year cardiovascular disease (CVD) risk compared to semaglutide (1.7 or 2.4 mg) in individuals with obesity without diabetes or prior CVD.

If you have obesity and are at risk for heart disease but don't have diabetes, tirzepatide may offer better long-term heart protection than semaglutide. It is taken as a weekly injection and has been shown to reduce your predicted 10-year risk of cardiovascular events more than semaglutide. Discuss with your doctor if this medication is appropriate for your specific health profile.